IMMUNE & THYMIC / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to these two thymic research peptides.
What is thymulin?
Thymulin is a nine-amino-acid (nonapeptide) hormone produced exclusively by thymic epithelial cells. Its defining biological feature is zinc dependence: the peptide exists in two forms — a biologically inactive zinc-free apoform and a biologically active zinc-bound form (Zn-thymulin) — and only the zinc complex drives T-lymphocyte differentiation and immune-cell modulation [7]. It was originally isolated from porcine serum under the name FTS (facteur thymique serique), and the name "thymulin" was introduced when the essential role of zinc was established. Serum thymulin activity has been used experimentally as an indicator of zinc nutritional status [6].
Is thymulin the same as serum thymic factor (FTS)?
They refer to the same molecule in different formulations. FTS (facteur thymique serique, or serum thymic factor) is the original name for the nonapeptide isolated from serum. "Thymulin" is the name introduced once researchers demonstrated that the peptide is biologically active only when bound to zinc — so technically, thymulin refers specifically to the zinc-bound, active form (FTS-Zn), while the zinc-free form is sometimes called the FTS apoform [7]. In contemporary literature the terms FTS and thymulin are used interchangeably for the same nonapeptide sequence, with the understanding that activity requires zinc.
How is thymulin different from thymosin alpha-1?
They are chemically and pharmacologically distinct molecules that both originate in the thymus gland. Thymulin is a nine-amino-acid nonapeptide whose activity is strictly zinc-dependent; it acts primarily as a hormonal signal that drives T-lymphocyte differentiation inside and leaving the thymus, and it participates in the thymus-neuroendocrine axis [4][7]. Thymosin alpha-1 is a 28-amino-acid acetylated polypeptide that acts on the innate-adaptive immune interface through dendritic-cell TLR signaling and T-cell maturation, and it has been approved as a drug in more than 35 countries [9]. The two molecules have different sequences, different molecular weights, different mechanisms, and very different clinical evidence bases — they are not interchangeable.
What does thymulin do for the immune system?
In its zinc-bound active form, thymulin drives the differentiation and maturation of T lymphocytes within and exiting the thymus, promotes balanced T-helper cell subsets, and modulates natural killer cell activity [4]. Beyond the lymphoid compartment, it participates in a bidirectional signaling axis with the anterior pituitary (the thymus-neuroendocrine axis), acting as a hypophysiotropic peptide while being regulated by neuroendocrine hormones [4]. In animal studies, it has also shown anti-inflammatory activity — reducing NF-kB and SAPK/JNK signaling, lowering pro-inflammatory cytokines, and modulating heat-shock protein expression in LPS-challenged mice [3]. Almost all of this evidence is preclinical.
What is thymosin alpha-1 used for?
In the clinical settings where it is approved internationally, thymosin alpha-1 (thymalfasin) is used for chronic viral hepatitis B and C (as an immune-stimulating adjuvant to antiviral therapy) and for immune reconstitution in severely immunocompromised patients [9]. Research settings have also studied it in sepsis (with mixed results including a 2025 null Phase 3 trial [8]), severe COVID-19 (where a retrospective cohort found mortality reduction and reversal of T-cell exhaustion [10]), and as a combination immunoadjuvant in cancer chemotherapy and immunotherapy protocols [11]. It is not FDA-approved for marketing in the United States.
Is thymosin alpha-1 FDA-approved?
No, not for marketing in the United States. Thymalfasin (synthetic thymosin alpha-1) is approved as a prescription drug in more than 35 other countries — primarily for chronic hepatitis B and C and immune reconstitution — but it does not hold an FDA marketing authorization for any indication in the US [9]. US use is limited to investigational protocols and compounding pharmacy contexts. The FDA has reviewed bulk drug substances including thymosin alpha-1-related compounds in the context of 503A compounding and has not formally endorsed them, reflecting unresolved questions about clinical evidence and quality for compounded use.
What happened in the 2025 TESTS sepsis trial?
The TESTS trial was a multicenter, double-blind, randomized, placebo-controlled Phase 3 trial involving 1,106 adult sepsis patients across 22 centers — the largest and most rigorous trial of thymosin alpha-1 ever conducted. It found no statistically significant difference in 28-day all-cause mortality between the thymosin alpha-1 group (23.4%) and placebo (24.1%): hazard ratio 0.99 (95% CI 0.77–1.27), P=0.93 [8]. This null result directly contradicts the expectation built up from smaller, lower-quality positive sepsis studies — including the earlier ETASS trial, whose near-significant mortality reduction (26.0% vs 35.0%, P=0.049) did not hold in the rigorous follow-up. The honest interpretation is that thymosin alpha-1 does not reduce sepsis mortality in the general ICU population, based on the current best evidence.
What is thymulin's relationship to zinc?
Zinc is not an optional cofactor for thymulin — it is a structural requirement for biological activity. Removing zinc from the peptide using a chelating agent completely abolishes its activity in T-cell assays; adding zinc back at a 1:1 molar ratio restores it fully [7]. The zinc ion coordinates to specific positions in the nonapeptide to produce the conformation the molecule needs to bind its receptor. This means serum thymulin activity in a living organism reflects both thymic peptide production and the host's zinc status simultaneously: in mild human zinc deficiency, serum thymulin activity fell even when plasma zinc appeared normal, and was restored by zinc supplementation [6]. Thymulin-specific findings in vivo are therefore always partially confounded by zinc.
How does thymosin alpha-1 work in severe COVID-19?
Severe COVID-19 is characterized in many patients by lymphocytopenia (very low T-cell counts) and T-cell exhaustion — CD8+ cytotoxic T cells that overexpress the checkpoint inhibitors PD-1 and Tim-3, which blunt their effectiveness against virus-infected cells. In a retrospective cohort of 76 severe COVID-19 patients, thymosin alpha-1 treatment was associated with significantly reduced mortality (11.11% vs 30.00%, P=0.044), increases in blood T-cell counts in lymphocytopenic patients, and reduced PD-1 and Tim-3 expression on CD8+ T cells, effectively reversing T-cell exhaustion [10]. The effect was most pronounced in elderly patients, whose immune senescence may make them more responsive to thymic immunostimulation. This is a retrospective cohort — not a randomized trial — so it establishes an association, not a causal proof.
Can thymulin and thymosin alpha-1 be combined?
There is no peer-reviewed literature on combining thymulin and thymosin alpha-1, and this desk does not advise on use, dosing, or combination protocols. The two compounds have distinct mechanisms — thymulin acts as a zinc-dependent hormonal signal at the thymic level, while thymosin alpha-1 acts through TLR signaling at the dendritic-cell level — and they have never been studied together in any published research [4][7][9]. Any claim about additive or synergistic effects is unsupported speculation. Both compounds are handled as research peptides in the US, and any discussion of their combined use falls entirely outside the scope of this digest.
What is the difference between thymulin, thymosin alpha-1, thymalin, and thymopentin?
Consumer sources conflate these routinely, but they are distinct: Thymulin is a nine-amino-acid zinc-dependent nonapeptide hormone secreted by thymic epithelial cells [7]. Thymosin alpha-1 (thymalfasin) is a 28-amino-acid acetylated polypeptide, the drug described on this page [9]. Thymalin is a bovine thymic glandular complex — a biological extract from calf thymus, not a defined single molecule — developed in Russia and unrelated in structure to either thymosin alpha-1 or thymulin. Thymopentin is a five-amino-acid synthetic peptide corresponding to a fragment of thymosin beta-1. Thymosin beta-4 (and its marketed fragment TB-500) is an entirely different actin-binding protein with no structural or functional relationship to thymosin alpha-1 or thymulin. None of the findings for one of these applies to any other.